期刊文献+

Golgi protein-73:A biomarker for assessing cirrhosis and prognosis of liver disease patients 被引量:25

下载PDF
导出
摘要 BACKGROUND Reliable biomarkers of cirrhosis,hepatocellular carcinoma(HCC),or progression of chronic liver diseases are missing.In this context,Golgi protein-73(GP73)also called Golgi phosphoprotein-2,was originally defined as a resident Golgi type II transmembrane protein expressed in epithelial cells.As a result,GP73 expression was found primarily in biliary epithelial cells,with only slight detection in hepatocytes.However,in patients with acute or chronic liver diseases and especially in HCC,the expression of GP73 is significantly up-regulated in hepatocytes.So far,few studies have assessed GP73 as a diagnostic or prognostic marker of liver fibrosis and disease progression.AIM To assess serum GP73 efficacy as a diagnostic marker of cirrhosis and/or HCC or as predictor of liver disease progression.METHODS GP73 serum levels were retrospectively determined by a novel GP73 ELISA(QUANTA Lite®GP73,Inova Diagnostics,Inc.,Research Use Only)in a large cohort of 632 consecutive patients with chronic viral and non-viral liver diseases collected from two tertiary Academic centers in Larissa,Greece(n=366)and Debrecen,Hungary(n=266).Aspartate aminotransferase(AST)/Platelets(PLT)ratio index(APRI)was also calculated at the relevant time points in all patients.Two hundred and three patients had chronic hepatitis B,183 chronic hepatitis C,198 alcoholic liver disease,28 autoimmune cholestatic liver diseases,15 autoimmune hepatitis,and 5 with other liver-related disorders.The duration of follow-up was 50(57)mo[median(interquartile range)].The development of cirrhosis,liver decompensation and/or HCC during follow-up were assessed according to internationally accepted guidelines.In particular,the surveillance for the development of HCC was performed regularly with ultrasound imaging and alpha-fetoprotein(AFP)determination every 6 mo in cirrhotic and every 12 mo in non-cirrhotic patients.RESULTS Increased serum levels of GP73(>20 units)were detected at initial evaluation in 277 out of 632 patients(43.8%).GP73-seropositivity correla
出处 《World Journal of Gastroenterology》 SCIE CAS 2020年第34期5130-5145,共16页 世界胃肠病学杂志(英文版)
  • 相关文献

参考文献3

二级参考文献56

  • 1Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G,Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J,Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982. 被引量:1
  • 2Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24:38-47. 被引量:1
  • 3Daleko$ GN, Christodoulou D, Kistis K, Zervou EK, Hatzis J,Tsianos EV. A prospective evaluation of dermatological sideeffects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 1998; 10:933-939. 被引量:1
  • 4Clifford BD, Donahue D, Smitt~ L, Cable E, Luttig B, Manns M, Bonkovsky HL. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613-619. 被引量:1
  • 5Noda K, Enomoto N, Arai K, Masuda E, Yamada Y, Suzuki K,Tanaka M, Yoshihara H. Induction of antinuclear antibody after interferon therapy in patients with type-C chronic hepatitis: its relation to the efficacy of therapy. Scand J Gastroenterol 1996; 31:716-722. 被引量:1
  • 6Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Blanch G, Zauli D, Bianchi FB. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.Hepatology 1997; 26:561-566. 被引量:1
  • 7Muratori P, Muratori L, Verucchi G, Attard L, Bianchi FB,Lenzi M. Non-organ-specific autoantibodies in children with chronic hepatitis C: clinical significance and impact on interferon treatment. Clin Infect Dis 2003; 37:1320-1326. 被引量:1
  • 8Agarwal N, Handa R, Acharya SK, Wali JP, Dinda AK,Aggarwal P. A study of autoimmune markers in hepatitis Cinfection. Indian J Med Res 2001; 113:170-174. 被引量:1
  • 9Wada M, Kang KB, Kinugasa A, Shintani S, Sawada K, Nishigami T, Shimoyama T. Does the presence of serum autoaritibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C? Intern Med 1997; 36:248-254. 被引量:1
  • 10Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C,Lorenzen J, Matern S, Lammert F. The presence of non-organspecific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infectious Diseases 2004; 4:4-12. 被引量:1

共引文献30

同被引文献185

引证文献25

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部